



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/997,191	11/20/2001	D. Wade Walke	LEX-0270-USA	4055

7590

02/20/2003

Lance K. Ishimoto
Lexicon Genetics Incorporated
4000 Research Forest Drive
The Woodlands, TX 77381

EXAMINER

DEBERRY, REGINA M

ART UNIT

PAPER NUMBER

1647

DATE MAILED: 02/20/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/997,191

Applicant(s)

WALKE ET AL.

Examiner

Regina M. DeBerry

Art Unit

1647

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 13 May 2002.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-4 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-4 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 5. 6) ☐ Other: _____

Status of Application, Amendments and/or Claims

The information disclosure statement filed 15 May 2002 (Paper No. 5) was received and complies with the provisions of 37 CFR §§1.97 and 1.98. It has been placed in the application file and the information referred to therein has been considered as to the merits.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-4 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility. The claims are directed to isolated cDNA molecules, isolated cDNA molecules encoding a polypeptide, vector and isolated protein.

The specification states that novel human protein (NHP) claimed in the instant application share sequence similarity with mammalian Wnt proteins. Wnt family proteins are a class of secreted growth and signaling factors that have been implicated in a number of biological processes such as blood cell formation, cancer, homeostasis, development, weight regulation and inflammation.

Generally, the art acknowledges that function cannot be predicted based solely on structural similarity to a protein found in the sequence databases. For example, Skolnick *et al.* (2000, Trends in Biotech. 18:34-39) state that knowing the protein

Art Unit: 1647

structure by itself is insufficient to annotate a number of functional classes, and is also insufficient for annotating the specific details of protein function (see Box 2, p. 36). The assertion that NHP has biological activities similar to known Wnt proteins cannot be accepted in the absence of supporting evidence, because the relevant literature reports examples of polypeptide families wherein individual members have distinct, and sometimes even opposite, biological activities. Bejsovec (1999, *Current Biology* 9:R684-R687) states that the same Wnt pathway can, in different contexts, have very different characteristics and consequences. Wnt signaling in worms appears to be fundamentally different than flies and vertebrates. For example fly Zw3 and mammalian GSK3 negatively regulate the pathway by contributing to the degradation of Armadillo/ β catenin, the worm GSK3 appears to act positively in the P2 signaling event (page R685, 2nd paragraph-1st paragraph, page R686). In addition, polynucleotides are known in the art to encode polypeptides, yet the polypeptides have no known function.

Martinez Arias *et al.* (1999, *Current Opinion in Genetics and Development* 9:447-454) establishes that loss of function studies of Wnt genes have revealed a high degree of pleiotropy, especially when the Wnt family is considered as a whole. Furthermore, Wnt proteins have been shown to interact with several different extracellular or cell-surface molecules such as Frizzled and Notch. The specification, however, does not disclose any information regarding true binding partners or functional characteristics/mechanisms of action of NHP.

The specification asserts several utilities, however the claimed invention lacks specific and substantial utility. A process to screen for receptor agonists and/or

antagonists, using probes to isolate other cDNAs with high sequence similarity, making antibodies, and chromosome mapping are not specific utilities. Agonist/antagonist assays are performed for any receptor-ligand pair when the physiological role of each is unknown. Antibodies can be made to any protein. A probe is a general utility that would be applicable to the broad class of the invention. A specific utility is a utility that is specific to the subject matter claimed. This contrasts with a general utility that would be applicable to the broad class of the invention. Indeed, the utility of a claimed DNA does not necessarily depend on the function of the encoded gene product, if the claimed DNA had a specific and substantial utility such as it hybridizes near a disease-associated gene or it has a gene regulating activity. The specification, however, fails to disclose that the DNA of NHP can be linked to a specific disease or gene regulating activity. Specific and substantial utilities amount to more than a starting point for further research and investigation. It does not require or constitute carrying out further research to identify or reasonably confirm what the practical use might ultimately be.

The specification states that agonists/antagonists for NHP may be employed as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances (page 3). It does not disclose any working examples demonstrating that specific agonists/antagonists of NHP were used to treat any condition.

The specification cites the use of NHP oligonucleotides in microarrays or high-throughput chip format (pages 6-8). However, without a disclosure of a particular disease state in which the claimed polynucleotides are expressed at an altered level or

form, it would be impossible to determine what the results of a gene expression monitoring assay mean. For example, if a compound is tested on a microarray comprising the claimed polynucleotides and affects expression of the polynucleotides negatively, it cannot be determined if that means that the compound is a potential good drug for a disease or would exacerbate the disease if administered. The test results also would not have meaning in terms of what specific disease is relevant. The asserted utility in gene expression monitoring assays is thus not substantial, because significant further research would have to be conducted to determine which diseases correlate with altered forms or levels of the claimed polynucleotides, and whether the claimed polynucleotides are overexpressed or underexpressed in the diseased tissue. Furthermore, since the disclosure does not disclose specific diseases that should be treated with the protein, drug discovery and determining toxicity levels would be quite meaningless.

The specification states that a genomic library can be constructed using DNA obtained from an individual suspected of carrying, or known to carry, a mutant NHP allele. The specification lists a group of disparate conditions that a person carrying a mutant NHP allele would present (page 13). However, the specification never establishes a connection between NHP and any of these conditions. There is no correlation to the predisposition of a particular disease and the claimed invention. Further experimentation is required before this asserted utility is substantial.

The instant application has failed to provide guidance as to how one of skill in the art could use the claimed invention in a way that constitutes a specific or substantial

Art Unit: 1647

utility. The proposed uses of the claimed invention are simply starting points for further research and investigation into potential practical uses of the claimed polypeptide.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-4 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific and substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 2 and 4 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 is drawn to an isolated cDNA molecule comprising a nucleotide sequence that: (b) hybridizes under highly stringent conditions to the nucleotide sequence of SEQ ID NO:1 or the complement thereof.

Art Unit: 1647

Stringency is relative, and the art does not recognize a single set of conditions as stringent. The specification also does not provide an unambiguous definition for the term. In the absence of a recitation of clear hybridization conditions (e.g., "hybridizes at wash conditions of A X SSC and B % SDS at CoC"), the claims fail to define the metes and bounds of the varying structures of polynucleotides recited in the claimed methods.

Claim 4 is indefinite because it is unclear what is meant by a "substantially isolated protein".

Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Regina M. DeBerry whose telephone number is (703) 305-6915. The examiner can normally be reached on Mondays-Fridays 8:00 a.m. - 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Kunz can be reached on (703) 308-4623. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

RMD

RMD
February 11, 2003

Elizabeth C. Summer

ELIZABETH C. SUMMER
FEBRUARY 11, 2003